INSULIN Act of 2026

The bill mandates significant regulatory changes impacting the healthcare sector. Title I caps patient out-of-pocket costs for insulin and removes deductibles, shifting more financial burden to health insurance issuers. Title II requires Pharmacy Benefit Managers (PBMs) to pass through 100% of insulin-related rebates to health plans, directly impacting PBM revenue models. Title III aims to accelerate generic and biosimilar competition by deterring delay tactics and expediting FDA review, which would negatively affect branded insulin manufacturers but benefit generic/biosimilar producers. Title IV establishes a pilot program and resource center to help uninsured individuals access affordable insulin, which could increase dispensing volume for retail pharmacies. Overall, the dominant impact on integrated health insurers/PBMs and branded pharma is negative, while generic/biosimilar manufacturers and retail pharmacies see positive effects.